Compare iShares MSCI Indonesia ETF (EIDO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.47, while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). Which is the better fit depends on your goals.
| EIDO | RXRX | |
|---|---|---|
52-Week High | $19.22 | $6.79 |
52-Week Low | $10.80 | $2.84 |
Market Cap | — | $1.81B |
Sector | — | Health |
Enterprise Value | — | $1.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
